We conducted an open-label, dose-escalation phase 1 clinical trial (CTR20210349) from July 19, 2021 to June 9, 2023, to study the safety and efficacy of autologous P63+ lung progenitor cell transplantation in patients with IPF. The gene discussed is TP63; the disease is idiopathic pulmonary fibrosis.